肺炎支原体大环内酯类抗生素全球耐药现状和耐药机制研究进展  

Progress in global drug resistance patterns and drug resistance mechanisms of Mycoplasma pneumoniae

作　　者：李少丽[1] 孙红妹[1] Li Shaoli;Sun Hongmei(Department of Bacteriology, Capital Institute of Pediatrics, Beijing 100020, China)

机构地区：[1]首都儿科研究所细菌研究室,北京100020

出　　处：《中华微生物学和免疫学杂志》2018年第5期395-400,共6页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金资助项目（81601778,81672062）;北京市优秀人才资助项目（2015000021469G192）

摘　　要：肺炎支原体已成为社区获得性肺炎的首要致病菌，每3～7年在世界范围内暴发流行一次，其引起的临床症状多样化。自2000年开始，肺炎支原体的大环内酯类抗生素耐药现象快速增长，席卷全球多个国家，在某些地区其耐药率甚至高达100%，给人类的健康带来了巨大威胁。本文将对肺炎支原体的全球耐药状况和耐药机制等方面进行综述。Mycoplasma pneumoniae （M.pneumoniae） is one of the predominant pathogenic bacteria causing community acquired pneumonia. An epidemic of M. pneumoniae infection occurs every three to seven years worldwide. It can cause a variety of clinical symptoms. Since 2000, macrolide-resistant M. pneumoniae strains have become increasingly common in many countries around the world and the drug resistance rate has reached as high as 100% in some area, which has posed a great threat to human health. This paper will review the status and mechanism of drug resistance in M. pneumoniae.

关 键 词：肺炎支原体 全球耐药 耐药机制 

分 类 号：R446.5[医药卫生—诊断学]